Navigating Your Journey: What Happens If You Get Pregnant While Taking Mounjaro

Last reviewed: July 14, 2026

Last updated: July 14, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Tirzepatide, a dual GLP-1 and GIP receptor agonist marketed as Mounjaro, has not been studied in pregnant patients, and animal reproduction studies have raised potential concerns about fetal development. If you discover you are pregnant while taking tirzepatide, stopping the medication promptly and consulting your healthcare provider is the essential first step to protect both your health and your pregnancy.

Why Tirzepatide Should Be Stopped During Pregnancy

Tirzepatide crosses the placental barrier and reaches fetal tissue in animal models. Preclinical studies in rats and rabbits at doses above those used in humans showed dose-dependent increases in fetal loss and developmental abnormalities, particularly affecting the pancreas and gastrointestinal system. While animal data does not always predict human outcomes, the FDA is not recommended during pregnancy equivalent, meaning risk in pregnancy clearly outweighs any potential benefit.

The mechanism of tirzepatide—activating GLP-1 and GIP pathways to slow stomach emptying and enhance insulin secretion—creates metabolic changes that are not appropriate during fetal development. Pregnancy itself triggers unique hormonal shifts in glucose metabolism, insulin sensitivity, and appetite regulation that require a different therapeutic approach than weight loss in non-pregnant populations. Continuing tirzepatide exposes the developing fetus to receptor signaling that has not been validated as safe during gestation.

Immediate Steps to Take When You Discover Pregnancy

Your first action should be to contact your prescribing physician and inform them of your positive pregnancy test. Do not stop tirzepatide abruptly without medical guidance, as your provider may recommend a tapering schedule or specific discontinuation timing based on your current dose and how far along you are in pregnancy. Your OB-GYN should also be notified so both your weight management physician and obstetric team can coordinate your care and monitor for any signs of adverse effects during early pregnancy.

PlexusDx can pause your tirzepatide subscription immediately upon your notification of pregnancy. Document your pregnancy status clearly in your patient account or contact PlexusDx support directly to ensure no further shipments arrive. Your healthcare team will advise whether any follow-up blood work or ultrasound imaging is needed to assess fetal development, particularly if you were several weeks into pregnancy when you discovered you were pregnant.

Pregnancy-Safe Weight Management Alternatives

Managing weight during pregnancy focuses on appropriate gestational weight gain rather than active weight loss. The American College of Obstetricians and Gynecologists recommends weight gain targets based on pre-pregnancy BMI: typically 25–35 pounds for women with overweight and 15–25 pounds for women with obesity. Structured nutritional counseling, supervised physical activity safe for pregnancy, and behavioral support replace pharmacotherapy as the cornerstones of healthy pregnancy weight management.

Some women who were on tirzepatide may experience rapid weight regain after stopping the medication, which is emotionally and physically challenging during pregnancy. Working with a registered dietitian who specializes in maternal nutrition and a prenatal care team experienced in high-BMI pregnancies can help you navigate this transition. Postpartum, after your healthcare provider clears you for breastfeeding cessation or completion, you and PlexusDx can discuss resuming tirzepatide or exploring other GLP-1 therapies as part of your longer-term weight management plan.

Genetic Insights and Personalized Pregnancy Planning

If you are planning pregnancy in the future and have been using PlexusDx tirzepatide, your Precision Peptide Genetic Test results—which map 14 metabolic pathways and 49 peptide-related genes—can inform your long-term weight management strategy after pregnancy and breastfeeding. Genetic variants in GLP1R, GIPR, FTO, and MC4R influence how your body responds to GLP-1 and GIP signaling, and understanding your individual genetic profile helps your care team design the most effective post-pregnancy treatment plan when you are ready to restart pharmacotherapy.

Pre-conception counseling can leverage your genetic insights to prepare for pregnancy while minimizing rapid weight regain postpartum. If you carry genetic variants associated with higher insulin resistance or greater appetite signaling, your postpartum strategy may prioritize earlier intervention with resumed tirzepatide therapy, combined with structured lifestyle support. PlexusDx supports this forward-looking approach by having your genetic and treatment history ready to inform safe, personalized decisions as you transition through pregnancy and into the postpartum period.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection is $289/mo month-to-month, or from $249/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

What should I do immediately if I find out I'm pregnant while taking tirzepatide?

Contact your prescribing physician and your OB-GYN right away to report your pregnancy and current tirzepatide use. Do not stop the medication on your own without medical guidance. Notify PlexusDx support to pause your tirzepatide subscription. Your healthcare team will determine the safest discontinuation plan based on how far along you are and your current dose.

Is there any evidence that tirzepatide is safe during pregnancy?

No. Tirzepatide has not been studied in pregnant women, and animal reproduction studies showed fetal harm at doses relevant to human use. The FDA considers tirzepatide contraindicated in pregnancy, meaning the risks clearly outweigh any benefits. Stopping tirzepatide is the standard of care once pregnancy is confirmed.

Will I regain weight quickly after stopping tirzepatide for pregnancy?

Many patients experience weight regain after stopping GLP-1 therapy, and pregnancy hormones can amplify this effect. Working with a prenatal dietitian and your care team on appropriate gestational weight gain targets can help manage this transition. After pregnancy and breastfeeding cessation, you can discuss restarting tirzepatide or other weight management options with your healthcare provider and PlexusDx.

Can I use PlexusDx tirzepatide again after I finish breastfeeding?

Yes. PlexusDx tirzepatide (compounded injection at $289/mo month-to-month, or from $249/mo on the 6-month plan) can be restarted after you and your physician confirm it is safe—typically after breastfeeding is complete or per your doctor's guidance. Your PlexusDx account and previous genetic test results remain on file to help inform your return to personalized weight management therapy.

How does my PlexusDx Precision Peptide Genetic Test help with postpartum weight management planning?

No — the Precision Peptide Genetic Test does not predict your response to tirzepatide or any specific medication. It analyzes pathway-level variants (GLP1R, GIPR, FTO, and MC4R) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.

Related Reading

• What Determines If You Are A Morning Person Or A Night Owl
• Can You Avoid Diabetes If It Runs In Your Family
• Hers Mounjaro
• Hims Mounjaro

Pricing and availability current as of July 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.